Skip to main content

Share story

Infrastructure Products

Microsoft plans to phase out Windows Deployment Services

Microsoft plans to phase out Windows Deployment Services Image: Primary
Microsoft plans to deprecate Windows Deployment Services with the next Windows Server release, beginning the phaseout of a tool administrators use to install Windows across fleets of computers over a network. The change covers the built-in server role, its management tools and its network boot functions. Microsoft says it will eventually remove the service. Administrators using Configuration Manager with Windows Deployment Services for network boot or multicast deployment are being advised to migrate those dependencies. The service will continue to work on currently supported Windows Server versions, including Windows Server 2025 and earlier; independent deployment products that do not rely on it are unaffected.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from BleepingComputer and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.